CN100500201C - Chinese herbal medicine for treating prostatitis - Google Patents
Chinese herbal medicine for treating prostatitis Download PDFInfo
- Publication number
- CN100500201C CN100500201C CNB200610113092XA CN200610113092A CN100500201C CN 100500201 C CN100500201 C CN 100500201C CN B200610113092X A CNB200610113092X A CN B200610113092XA CN 200610113092 A CN200610113092 A CN 200610113092A CN 100500201 C CN100500201 C CN 100500201C
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- radix
- portions
- chinese herbal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000411851 herbal medicine Species 0.000 title claims abstract description 10
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 9
- 241000218176 Corydalis Species 0.000 claims abstract description 10
- 241000241550 Cyathula Species 0.000 claims abstract description 7
- 241000756943 Codonopsis Species 0.000 claims description 9
- 241000283956 Manis Species 0.000 claims description 9
- 241000131808 Scolopendra Species 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 241000545442 Radix Species 0.000 claims description 6
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 240000006927 Foeniculum vulgare Species 0.000 abstract 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 15
- 210000002307 prostate Anatomy 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 206010020718 hyperplasia Diseases 0.000 description 10
- 206010020880 Hypertrophy Diseases 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 235000012907 honey Nutrition 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 210000003708 urethra Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037544 Purging Diseases 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese herbal medicine for treating prostatitis, which is prepared from Chinese angelica, medicinal cyathula root, root of red rooted saliva, burred tuber, zedoary, corydalis tuber, centipede, dandelion, astragalus root, pangolin scales, cyperus tuber, fennel and pilose asiabell root.
Description
Technical field
The present invention relates to a kind of Chinese herbal medicine for the treatment of prostatitis, is that a kind of main treatment prostate hyperplasia, inflammation, hypertrophy and calculus of urethra are the Chinese patent medicine of raw material with the Chinese herbal medicine.
Background technology
Prostate hyperplasia, inflammation, hypertrophy are a kind of old people's commonly encountered diseases, as early treatment not, can make the bladder muscle plumpness, make the urethra distortion, increase the contractility of bladder, just can make urethra pass through to block and discharge, go down for a long time, bladder loses contractility, urine backflow ureter, cause ureter to enlarge, kidney is simultaneously loose, and atrophy causes that pollakiuria, incontinence, inflammation, related symptoms such as hemorrhage take place, serious can't take care of oneself, even causes the uremic card and death.Current, treatment prostate hyperplasia, inflammation, hypertrophy Western medicine commonly used and operation, these Western medicine not only cost an arm and a leg, and toxic and side effects is also higher, and operation increases the patient suffering, and can not effect a radical cure.Utilization Chinese herbal treatment or auxiliary smelting treatment prostate hyperplasia, inflammation, hypertrophy are the work of always studying, but present medicine can only alleviate the patient suffering, can not effect a radical cure, and curative effect can not be satisfactory.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese herbal medicine for the treatment of prostatitis, can treat and effect a radical cure prostate hyperplasia, inflammation and hypertrophy, and calculus of urethra is also had better curative effect.
Solution of the present invention is according to the rule of the traditional Chinese medical science to prostate hyperplasia, inflammation, hypertrophy treatment, be the body resistance strengthening and constitution consolidating, the kidney invigorating collateral dredging, blood circulation promoting and blood stasis dispelling, the detoxifcation pain relieving, hard masses softening and resolving and dampness removing fluid-purging therapy, the present invention forms according to above-mentioned rule, can the kidney invigorating collateral dredging, blood circulation promoting and blood stasis dispelling, the detoxifcation pain relieving again can the body resistance strengthening and constitution consolidating, hard masses softening and resolving.Radix Cyathulae of the present invention, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Rhizoma Curcumae and Squama Manis are gone into the heart, lung, liver three warps, be used to invigorate blood circulation, and invigorating the liver and kidney, blood circulation regulating, removing blood stasis with potent drugs is by blood; Rhizoma sparganic and Scolopendra wind-damp dispelling, dampness is stimulated the menstrual flow, and is relieving convulsion, wind-transformation expectorant; The Rhizoma Corydalis promoting the circulation of blood is stimulated the menstrual flow, removing blood stasis with potent drugs pursues blood, the long-pending painful abdominal mass that disappears of mill, detumescence convergence; Fructus Foeniculi and Rhizoma Cyperi warming spleen and stomach for dispelling cold, analgesia, Shujin, suppressing the hyperactive liver and easing the stomach; The Radix Codonopsis and the Radix Astragali, Herba Taraxaci benefiting vital QI and blood, promoting the production of body fluid to quench thirst, promoting pus discharge and tissue regeneration strengthening, invigorating QI to consolidate the body surface resistance, diuresis detoxifcation; Have eliminating evil just the wound, set upright and do not stay heresy, the kidney invigorating collateral dredging, warm network blood-activating analgetic, hard masses softening and resolving makes the function of fortuneization urine diuresis, is antiinflammatory, the medicament of the edema of dispelling, diuresis, the kidney invigorating water, has the sick effect of good radical cure.
The present invention is made by the following weight proportion raw material:
11～19 parts of 25～33 parts of Radix Salviae Miltiorrhizaes of 11～19 portions of Radix Cyathulaes of Radix Angelicae Sinensis
11～19 parts of 6～14 parts of Rhizoma Corydalis of 6～14 parts of Rhizoma Curcumae of rhizoma sparganic
26～34 parts of 28～36 parts of Radixs Astragali of 1～3 part of Herba Taraxaci of Scolopendra
6～14 parts in 11～19 portions of Fructus Foeniculis of 6～14 portions of Rhizoma Cyperis of Squama Manis
27～35 parts of Radix Codonopsis.
The weight proportion of each raw material of formula optimization of the present invention is:
13～17 parts of 27～31 parts of Radix Salviae Miltiorrhizaes of 13～17 portions of Radix Cyathulaes of Radix Angelicae Sinensis
13～17 parts of 8～12 parts of Rhizoma Corydalis of 8～12 parts of Rhizoma Curcumae of rhizoma sparganic
28～32 parts of 30～34 parts of Radixs Astragali of 1.5～2.5 parts of Herba Taraxacis of Scolopendra
8～12 parts in 13～17 portions of Fructus Foeniculis of 8～12 portions of Rhizoma Cyperis of Squama Manis
29～33 parts of Radix Codonopsis.
The weight proportion of best each raw material of prescription of the present invention is:
15 parts of 29 parts of Radix Salviae Miltiorrhizaes of 15 portions of Radix Cyathulaes of Radix Angelicae Sinensis
15 parts of 10 parts of Rhizoma Corydalis of 10 parts of Rhizoma Curcumae of rhizoma sparganic
30 parts of 32 parts of Radixs Astragali of 2 parts of Herba Taraxacis of Scolopendra
10 parts in 15 portions of Fructus Foeniculis of 10 portions of Rhizoma Cyperis of Squama Manis
31 parts of Radix Codonopsis.
The present invention can be made into capsule, be called " prostatitis must health ball " method for making and be get Radix Angelicae Sinensis, Radix Cyathulae, Radix Salviae Miltiorrhizae,
Rhizoma sparganic, Rhizoma Curcumae, Rhizoma Corydalis, Scolopendra, Herba Taraxaci, the Radix Astragali, Squama Manis, Rhizoma Cyperi, Fructus Foeniculi, Radix Codonopsis drying and crushing to 80～120 order fine powders, add the refined honey mix homogeneously in the fine powder after processing, refined honey adds 90 gram refined honeys by per 100 gram fine powders, the honeyed pill of making every ball 7 grammes per square metres gets final product, usage is a day clothes secondary, each ball.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1, the Chinese herbal medicine each component selected for use of the present invention meets the pharmaceutical control law regulation, utilizes comprehensive function treatment prostate hyperplasia, inflammation, the hypertrophy of the Chinese medicine of respectively distinguishing the flavor of, and does not have chemical sweeting agent, and is nontoxic to human body.Show that through animal acute toxicity test underproof animal end sees any toxic reaction, its main organs does not have tangible change yet, and mice is 40g crude drug/kg to the maximum tolerated dose of medicine of the present invention, is 156 times of clinical people's consumption, and safety of medicine is reliable.
2, the present invention need not decoct, no bitterness sense, rich in proteins, glucose, phlegmatic temperament, organic acid, fatty oil, ginsenoside, vitamin and nearly tens seed amino acids in the medicine, also contain various trace elements such as potassium, zinc, calcium, ferrum, be beneficial to absorption of human body, health invigorating, and taking convenience.
3, the present invention can treat and effect a radical cure prostate hyperplasia, inflammation, hypertrophy effectively, and calculus of urethra is also had better curative effect, has improved patient's life quality and the time greatly, and higher healing rehabilitation efficacy is arranged.
For showing medicine of the present invention, as follows through clinical test results to prostate hyperplasia, inflammation, outgrowth therapeutic effect; Treat various prostate hyperplasia, inflammation, hypertrophy patient's 67 examples, radical cure rehabilitation 45 examples, produce effects 12 examples, effective 3 examples, invalid 7 examples, effective percentage reaches more than 89%.Treatment calculus of urethra 40 examples, radical cure rehabilitation 20 examples, produce effects 8 examples, effective 3 examples, invalid 9 examples, effective percentage reaches more than 77%.For example: Cai so-and-so, man, 45 years old, to suffer from prostate 5 years and go to a doctor on July 6th, 2003, readme hypogastric region portion weighs down and rises, symptoms such as urine duty.Take medicine of the present invention sx after 15 days, transference cure after 30 days does not have incompatible.Normal after checking, not recurrence so far.For another example: Zhang, man, 65 years old, to suffer from prostate 10 years and went to a doctor in 12nd in JIUYUE in 2005, readme urine is smooth, weigh down symptom such as rise.Take medicine of the present invention sx after 15 days, transference cure after two courses of treatment does not have incompatible.Rehabilitation after checking.
The specific embodiment
Take by weighing raw material by following proportioning: Radix Angelicae Sinensis 15g, Radix Cyathulae 29g, Radix Salviae Miltiorrhizae 15g, rhizoma sparganic 10g, Rhizoma Curcumae 10g, Rhizoma Corydalis 15g, Scolopendra 2g, Herba Taraxaci 32g, Radix Astragali 30g, Squama Manis 10g, Rhizoma Cyperi 15g, Fructus Foeniculi 10g, Radix Codonopsis 31g.With above-mentioned raw materials drying and crushing to 80～120 order fine powders, add the refined honey mix homogeneously in the fine powder after processing, refined honey adds 90 gram refined honeys by per 100 gram fine powders, and the honeyed pill of making every ball 7 grammes per square metres gets final product, and usage is a day clothes secondary, each ball.
Claims (3)
1, a kind of Chinese herbal medicine for the treatment of prostatitis is characterized in that it is made by the following weight proportion raw material:
11～19 parts of 25～33 parts of Radix Salviae Miltiorrhizaes of 11～19 portions of Radix Cyathulaes of Radix Angelicae Sinensis
11～19 parts of 6～14 parts of Rhizoma Corydalis of 6～14 parts of Rhizoma Curcumae of rhizoma sparganic
26～34 parts of 28～36 parts of Radixs Astragali of 1～3 part of Herba Taraxaci of Scolopendra
6～14 parts in 11～19 portions of Fructus Foeniculis of 6～14 portions of Rhizoma Cyperis of Squama Manis
27～35 parts of Radix Codonopsis.
2, a kind of Chinese herbal medicine for the treatment of prostatitis according to claim 1, wherein the weight proportion of each raw material is:
13～17 parts of 27～31 parts of Radix Salviae Miltiorrhizaes of 13～17 portions of Radix Cyathulaes of Radix Angelicae Sinensis
13～17 parts of 8～12 parts of Rhizoma Corydalis of 8～12 parts of Rhizoma Curcumae of rhizoma sparganic
28～32 parts of 30～34 parts of Radixs Astragali of 1.5～2.5 parts of Herba Taraxacis of Scolopendra
8～12 parts in 13～17 portions of Fructus Foeniculis of 8～12 portions of Rhizoma Cyperis of Squama Manis
29～33 parts of Radix Codonopsis.
3, a kind of Chinese herbal medicine for the treatment of prostatitis according to claim 1, wherein the weight proportion of each raw material is:
15 parts of 29 parts of Radix Salviae Miltiorrhizaes of 15 portions of Radix Cyathulaes of Radix Angelicae Sinensis
15 parts of 10 parts of Rhizoma Corydalis of 10 parts of Rhizoma Curcumae of rhizoma sparganic
30 parts of 32 parts of Radixs Astragali of 2 parts of Herba Taraxacis of Scolopendra
10 parts in 15 portions of Fructus Foeniculis of 10 portions of Rhizoma Cyperis of Squama Manis
31 parts of Radix Codonopsis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610113092XA CN100500201C (en) | 2006-09-11 | 2006-09-11 | Chinese herbal medicine for treating prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610113092XA CN100500201C (en) | 2006-09-11 | 2006-09-11 | Chinese herbal medicine for treating prostatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101125186A CN101125186A (en) | 2008-02-20 |
| CN100500201C true CN100500201C (en) | 2009-06-17 |
Family
ID=39093378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200610113092XA Expired - Fee Related CN100500201C (en) | 2006-09-11 | 2006-09-11 | Chinese herbal medicine for treating prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100500201C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103028080A (en) * | 2012-01-04 | 2013-04-10 | 王遐 | Traditional Chinese medicine decoction for treating qi-stagnancy and blood stasis prostatitis |
| CN102580005A (en) * | 2012-03-23 | 2012-07-18 | 南宁市品迪生物工程有限公司 | Zhuang ethnic group medical secret recipe for treatment of prostatitis |
| CN103432431B (en) * | 2013-08-01 | 2015-05-27 | 马雨婷 | Traditional Chinese medicine for treating chronic prostatitis |
| CN104887773A (en) * | 2014-03-05 | 2015-09-09 | 鲍旭刚 | Prostatitis treating drug and preparation method thereof |
| CN106390039A (en) * | 2016-12-05 | 2017-02-15 | 黄于隆 | Traditional Chinese medicine composition and massage medicament for prostatitis and prostatic hyperplasia |
| CN112843200A (en) * | 2019-11-28 | 2021-05-28 | 吴智勇 | A Chinese medicinal composition for treating prostatitis and its preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772163A (en) * | 2005-09-02 | 2006-05-17 | 王增奎 | Chinese medicine for treating nonbacterial prostatitis and its prepn |
-
2006
- 2006-09-11 CN CNB200610113092XA patent/CN100500201C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772163A (en) * | 2005-09-02 | 2006-05-17 | 王增奎 | Chinese medicine for treating nonbacterial prostatitis and its prepn |
Non-Patent Citations (2)
| Title |
|---|
| 慢性前列腺炎从疡科辨治. 郑国珍，郭启先.福建中医药，第28卷第1期. 1997 * |
| 王益平，张娟莉，马宽玉. 名中医诊治慢性前列腺炎的经验及思路探析.中国中医基础医学杂志，第11卷第7期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101125186A (en) | 2008-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100500201C (en) | Chinese herbal medicine for treating prostatitis | |
| CN101862428B (en) | Chinese medicament for treating benign prostatic hyperplasia | |
| CN101125166A (en) | External-applied traditional Chinese medicine for treating rheumatism | |
| CN101380453B (en) | Oral powder and external plaster for treating hyperosteogeny and atrophic arthritis and production method thereof | |
| CN102961707A (en) | Traditional Chinese medicine for treating chronic renal failure | |
| CN102846903A (en) | Traditional Chinese medicinal preparation for treating chronic pyelonephritis | |
| CN1317021C (en) | Chinese medicinal formulation for stopping pain for removing Bi | |
| CN100544761C (en) | A kind of medicine for the treatment of coronary heart disease | |
| CN101940739A (en) | Traditional Chinese medicine for treating gout | |
| CN101721651B (en) | Traditional Chinese medicine capsule for treating scapulohumeral periarthritis | |
| CN101130052A (en) | Traditional Chinese medicine for treating postpartum arthralgia | |
| CN100421687C (en) | Chinese medicine for treating kidney insufficiency | |
| CN101002848B (en) | Medicine for treating recurrent uarthritis, and its preparing method | |
| CN101125174A (en) | Traditional Chinese medicine pill for treating chronic pharyngitis | |
| CN103550446B (en) | Traditional Chinese medicine composition for external use to treat rheumatoid arthritis and application of traditional Chinese medicine composition | |
| CN102973866B (en) | Traditional Chinese medicine compound navel patch for treating prostate disease | |
| CN100398143C (en) | Medicament for treating vitiligo | |
| CN101125180A (en) | Traditional Chinese medicine for curing rheumatism | |
| CN101301407B (en) | Medicament for treating arthritis and angiitis | |
| CN100427132C (en) | Traditional Chinese medicine for treating rheumatism and its preparing process | |
| CN1305505C (en) | Medicament for treating prostatauxe inflammation | |
| CN103550469B (en) | A kind of Chinese medicine composition for the treatment of lumbago disease | |
| CN102380009A (en) | Chinese herbal medicine powder for treating rheumatism and administration method thereof | |
| CN1305508C (en) | Pill for treating coronary heart disease | |
| CN102698126B (en) | Traditional Chinese medicine compound having effect of treating prostatitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: Department of ENT, Cangshan district hospital, Shandong Patentee after: Cai Shenghua Address before: Beijing city Haidian District Jimenqiao Jimen lane and garden 1 Building 1 Unit No. 201. Patentee before: Cai Shenghua |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090617 Termination date: 20120911 |